NO995617L - Anvendelse av en CD40:CD154 bindingsforstyrrer for å forhindre mot-adaptive immunresponser, spesielt transplantatavstoetning - Google Patents
Anvendelse av en CD40:CD154 bindingsforstyrrer for å forhindre mot-adaptive immunresponser, spesielt transplantatavstoetningInfo
- Publication number
- NO995617L NO995617L NO995617A NO995617A NO995617L NO 995617 L NO995617 L NO 995617L NO 995617 A NO995617 A NO 995617A NO 995617 A NO995617 A NO 995617A NO 995617 L NO995617 L NO 995617L
- Authority
- NO
- Norway
- Prior art keywords
- immune responses
- transplant rejection
- adaptive immune
- binding inhibitor
- prevent counter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4679197P | 1997-05-17 | 1997-05-17 | |
US4938997P | 1997-06-11 | 1997-06-11 | |
US8514598P | 1998-05-12 | 1998-05-12 | |
PCT/US1998/010075 WO1998052606A1 (en) | 1997-05-17 | 1998-05-15 | Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection |
Publications (2)
Publication Number | Publication Date |
---|---|
NO995617D0 NO995617D0 (no) | 1999-11-16 |
NO995617L true NO995617L (no) | 2000-01-17 |
Family
ID=27366975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO995617A NO995617L (no) | 1997-05-17 | 1999-11-16 | Anvendelse av en CD40:CD154 bindingsforstyrrer for å forhindre mot-adaptive immunresponser, spesielt transplantatavstoetning |
Country Status (20)
Country | Link |
---|---|
US (2) | US20020119150A1 (pl) |
EP (1) | EP0980259A1 (pl) |
JP (1) | JP2002500648A (pl) |
KR (1) | KR100575069B1 (pl) |
CN (1) | CN1202864C (pl) |
AU (1) | AU735592B2 (pl) |
BG (1) | BG64841B1 (pl) |
BR (1) | BR9809641A (pl) |
CA (1) | CA2291156A1 (pl) |
EA (1) | EA002549B1 (pl) |
EE (1) | EE9900528A (pl) |
HU (1) | HUP0003392A3 (pl) |
IL (1) | IL132882A0 (pl) |
IS (1) | IS5247A (pl) |
NO (1) | NO995617L (pl) |
NZ (1) | NZ500974A (pl) |
PL (1) | PL192521B1 (pl) |
SK (1) | SK156099A3 (pl) |
TR (1) | TR199902817T2 (pl) |
WO (1) | WO1998052606A1 (pl) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU768547B2 (en) * | 1999-01-08 | 2003-12-18 | Wisconsin Alumni Research Foundation | Methods of prolonging transplant survival using immunotoxins and costimulation blockade of CD154 and CD28 |
JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
JP2003512439A (ja) * | 1999-10-22 | 2003-04-02 | バイオジェン インコーポレイテッド | 眼の免疫学的合併症を処置するためのcd40:cd154結合遮断剤の使用 |
WO2001068133A1 (en) * | 2000-03-14 | 2001-09-20 | Genetics Institute, Inc. | Use of rapamycin and agents that inhibit b7 activity in immunomodulation |
WO2001079555A2 (en) | 2000-04-14 | 2001-10-25 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
AU2001261585B2 (en) | 2000-05-12 | 2006-08-31 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
CN1438894A (zh) * | 2000-06-09 | 2003-08-27 | 布里斯托尔-迈尔斯斯奎布公司 | 通过阻断淋巴细胞信号和阻断lfa-1介导的粘附作用调节细胞介导的免疫应答的方法 |
EP1179587A1 (de) * | 2000-08-09 | 2002-02-13 | Genethor GmbH | Verfahren zur Reduzierung von spezifischen Immunreaktionen |
KR20040023565A (ko) * | 2000-09-18 | 2004-03-18 | 아이덱 파마슈티칼즈 코포레이션 | B 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법 |
US9102726B2 (en) | 2002-12-04 | 2015-08-11 | Argos Therapeutics, Inc. | Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same |
NZ544486A (en) * | 2003-06-13 | 2009-04-30 | Biogen Idec Inc | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
CN101072587B (zh) | 2004-07-26 | 2012-12-26 | 比奥根艾迪克Ma公司 | 抗-cd154抗体 |
JP5014143B2 (ja) * | 2005-10-14 | 2012-08-29 | 学校法人福岡大学 | 膵島移植における移植膵島障害抑制剤 |
AR058135A1 (es) * | 2005-10-21 | 2008-01-23 | Chugai Pharmaceutical Co Ltd | Agentes para el tratamiento de cardiopatias |
AR057582A1 (es) * | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
EP1968386A4 (en) * | 2005-12-15 | 2009-07-22 | Univ New York State Res Found | METHOD FOR TREATING UNDERFUNCTION OF THE IMMUNE SYSTEM BY REGULATING THE CD40 LIGAND EXPRESSION |
US8771686B2 (en) * | 2006-01-27 | 2014-07-08 | Chugai Seiyaku Kabushiki Kaisha | Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody |
JP5754875B2 (ja) * | 2006-04-07 | 2015-07-29 | 国立大学法人大阪大学 | 筋再生促進剤 |
TWI438208B (zh) * | 2007-01-23 | 2014-05-21 | Chugai Pharmaceutical Co Ltd | 抑制慢性排斥反應之藥劑 |
CN104906581A (zh) * | 2008-06-05 | 2015-09-16 | 国立研究开发法人国立癌症研究中心 | 神经浸润抑制剂 |
GB0815788D0 (en) * | 2008-08-29 | 2008-10-08 | Isis Innovation | Therapeutic antibodies |
JP6051049B2 (ja) | 2010-05-28 | 2016-12-21 | 中外製薬株式会社 | 抗腫瘍t細胞応答増強剤 |
EP3229586A4 (en) | 2014-12-10 | 2018-10-24 | Regents of the University of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
MX2018001522A (es) | 2015-08-05 | 2018-03-15 | Janssen Biotech Inc | Anticuerpos anti-cd154 y metodos de uso de estos. |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
CN117843789A (zh) | 2017-05-24 | 2024-04-09 | Als治疗发展学会 | 治疗性抗cd40配体抗体 |
JP7235249B2 (ja) | 2017-10-20 | 2023-03-08 | 学校法人兵庫医科大学 | 抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU201095B (en) * | 1988-06-14 | 1990-09-28 | Richter Gedeon Vegyeszet | New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions |
US5104858A (en) * | 1988-09-29 | 1992-04-14 | Yale University | Sensitizing multidrug resistant cells to antitumor agents |
US5068323A (en) * | 1989-04-21 | 1991-11-26 | Merck & Co., Inc. | Thermally re-arranged FK-506 derivatives having immunosuppressant activity |
US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
ES2112431T3 (es) * | 1992-08-21 | 1998-04-01 | Genentech Inc | Procedimiento para el tratamiento de un trastorno mediado por lfa-1. |
JPH06298654A (ja) * | 1993-04-12 | 1994-10-25 | Sumitomo Electric Ind Ltd | 抗原特異的免疫抑制剤 |
US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
ATE219376T1 (de) * | 1996-03-20 | 2002-07-15 | Bristol Myers Squibb Co | Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung |
JP2001508450A (ja) * | 1997-01-10 | 2001-06-26 | バイオジェン インコーポレイテッド | 抗cd40l化合物の治療学的投与の方法 |
-
1998
- 1998-05-15 KR KR1019997010632A patent/KR100575069B1/ko not_active IP Right Cessation
- 1998-05-15 EA EA199901046A patent/EA002549B1/ru not_active IP Right Cessation
- 1998-05-15 JP JP55047798A patent/JP2002500648A/ja not_active Ceased
- 1998-05-15 BR BR9809641-9A patent/BR9809641A/pt not_active Application Discontinuation
- 1998-05-15 EE EEP199900528A patent/EE9900528A/xx unknown
- 1998-05-15 WO PCT/US1998/010075 patent/WO1998052606A1/en active IP Right Grant
- 1998-05-15 CA CA002291156A patent/CA2291156A1/en not_active Abandoned
- 1998-05-15 SK SK1560-99A patent/SK156099A3/sk not_active Application Discontinuation
- 1998-05-15 TR TR1999/02817T patent/TR199902817T2/xx unknown
- 1998-05-15 CN CNB988063417A patent/CN1202864C/zh not_active Expired - Fee Related
- 1998-05-15 AU AU74940/98A patent/AU735592B2/en not_active Ceased
- 1998-05-15 NZ NZ500974A patent/NZ500974A/en unknown
- 1998-05-15 IL IL13288298A patent/IL132882A0/xx not_active IP Right Cessation
- 1998-05-15 PL PL336994A patent/PL192521B1/pl not_active IP Right Cessation
- 1998-05-15 HU HU0003392A patent/HUP0003392A3/hu unknown
- 1998-05-15 EP EP98922381A patent/EP0980259A1/en not_active Ceased
-
1999
- 1999-11-12 IS IS5247A patent/IS5247A/is unknown
- 1999-11-16 NO NO995617A patent/NO995617L/no not_active Application Discontinuation
- 1999-12-03 BG BG103948A patent/BG64841B1/bg unknown
-
2002
- 2002-04-09 US US10/120,272 patent/US20020119150A1/en not_active Abandoned
-
2006
- 2006-12-12 US US11/638,218 patent/US20070244053A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PL336994A1 (en) | 2000-07-31 |
WO1998052606A1 (en) | 1998-11-26 |
KR100575069B1 (ko) | 2006-05-02 |
BG64841B1 (bg) | 2006-06-30 |
US20070244053A1 (en) | 2007-10-18 |
CN1202864C (zh) | 2005-05-25 |
AU735592B2 (en) | 2001-07-12 |
PL192521B1 (pl) | 2006-11-30 |
SK156099A3 (en) | 2000-06-12 |
CN1261284A (zh) | 2000-07-26 |
JP2002500648A (ja) | 2002-01-08 |
EP0980259A1 (en) | 2000-02-23 |
EE9900528A (et) | 2000-06-15 |
NZ500974A (en) | 2001-06-29 |
IS5247A (is) | 1999-11-12 |
EA002549B1 (ru) | 2002-06-27 |
IL132882A0 (en) | 2001-03-19 |
AU7494098A (en) | 1998-12-11 |
KR20010012671A (ko) | 2001-02-26 |
BG103948A (en) | 2000-07-31 |
CA2291156A1 (en) | 1998-11-26 |
US20020119150A1 (en) | 2002-08-29 |
HUP0003392A2 (hu) | 2001-08-28 |
NO995617D0 (no) | 1999-11-16 |
HUP0003392A3 (en) | 2002-09-30 |
EA199901046A1 (ru) | 2000-10-30 |
BR9809641A (pt) | 2000-07-11 |
TR199902817T2 (xx) | 2000-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO995617L (no) | Anvendelse av en CD40:CD154 bindingsforstyrrer for å forhindre mot-adaptive immunresponser, spesielt transplantatavstoetning | |
HK1031730A1 (en) | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | |
PL338987A1 (en) | 2-aminopyridines containing substituents in the form of condensed rings useful as nos inhibitors | |
HU1400034D0 (hu) | Biotin vagy biotin származékok és antitrombotikus hatású poliszacharidok között legalább egy kovalens kötést tartalmazó vegyületek által kiváltott vérzések kezelése | |
GB9920872D0 (en) | Benzophenones as inhibitors of reverse transcriptase | |
AU8704101A (en) | Novel cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications | |
PL362546A1 (pl) | Związki benzamidowe jako inhibitory sekrecji Apo B | |
EE200200192A (et) | 5-(2-asendatud-5-heterotsüklüülsulfonüülpürid-3-üül)dihüdropürasolo[4,3-d]pürimidii n-7-oonid kui fosfodiesteraasi inhibiitorid | |
DK0818448T3 (da) | Cycloalkanopyridiner som CETP-inhibitorer | |
PH31290A (en) | Heteroaryl amines as novel acetylcholinesterase inhibitors. | |
NO20004133L (no) | Antistoffer mot human CD40 | |
HK1022100A1 (en) | Reflux inhibitors | |
NO943852D0 (no) | Fremgangsmåte for å hemme bentap | |
IL153661A0 (en) | Piperidine compounds for use as ccr-3 inhibitors | |
NO20016319L (no) | VLA-4 inhibitor-forbindelser | |
AU2745597A (en) | Detergent compositions comprising modified polyamines as dye transfer inhibitors | |
DK1228073T3 (da) | Imidazolforbindelser som phosphodiesterase VII-inhibitorer | |
NO20016201D0 (no) | Tienopyrimidiner som fosfodiesteraseinhibitorer | |
SI1007512T1 (en) | Branched alkoxy-subsituted 2-aminopyridines as nos inhibitors | |
AU7087991A (en) | Tricyclic-cyclic amines as novel cholinesterase inhibitors | |
AU2001292276A1 (en) | Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient | |
KR940010109U (ko) | 미끄럼 방지를 위한 클러치용 스프링 | |
AU2002323537A1 (en) | Arylamines as inhibitors of chemokine binding to us28 | |
NO20006198D0 (no) | Fremgangsmåter for å inhibere TEF-3-aktivitet | |
ITPD940184A0 (it) | Cassetto polifunzionale per arredi commerciali. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |